MarketBeat
13 Sept 2026, 14:50 UTC · 6w ago
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Impact · against what's priced in
The article identifies binary clinical and regulatory catalysts for three small-cap biotechs, though these events are widely known risks in the sector. For KOD, widening losses increase the pressure on the DAYBREAK study, while CAPR and IVVD remain dependent on high-stakes FDA and Phase 3 outcomes to justify their current valuations.
- IVVD+0.60
No priced-in read yet
- In context
The upcoming Phase 3 DECLARATION study for VYD2311 represents a potential commercial expansion for the company beyond its current PEMGARDA product.
Read from the article alone
